Summary of Gel Procedures: (Bld Type, Abysc, AHG Crossmatch)

Blood Typing: Preparation of Red Blood Cells for Testing

Preparation of a 4% 1% suspension of red blood cells in MTS Diluent 2 PLUS for ABO forward grouping and D
antigen typing:
1. In a test tube labeled for the sample red blood cell suspension, dispense 0.5 mL of MTS Diluent 2 PLUS.
2. Add 50 L of anticoagulated whole blood or 25 L of packed red blood cells.
3. Mix gently to resuspend. The final red blood cell suspension should be 4% 1%.

ABO Forward and Reverse Grouping / D Antigen Typing Test Procedure

1. Visually inspect each gel card before use. Each microtube should have a clear liquid layer on top of the
opaque gel.
2. Label the gel card with the appropriate sample identification.
3. Remove the foil seal from the gel card.
4. Add 50 L of each of the 0.8% suspensions of reagent A 1 and B red blood cells to the labeled Buffered Gel
micro tubes.
5. Add 50 L of serum or plasma to the Buffered Gel microtubes.
6. Add 12.5 L of 4% 1% red blood cells diluted in MTS Diluent 2 PLUS to the Anti-A, Anti-B, Anti-D and
Control micro tubes.
7. Centrifuge the gel card in the MTS Centrifuge at the preset conditions.
8. For manual readings, observe the front and the back of each microtube macroscopically and record
reactions as described in the interpretation section of the MTS Gel Card package insert.

Antibody Screen Test Procedure (3 screening cells.)

1. Visually inspect each gel card before use. Each microtube should have a clear liquid layer on top of opaque
gel.
2. Label the MTS Anti-IgG Card with the appropriate identification.
3. Remove the foil seal from the gel card or from the individual microtubes used for testing.
4. Add 50 L of the 0.8% antibody screen red blood cell suspension to the microtube.
5. Add 25L of serum or plasma to the microtubes.
6. Incubate the MTS Anti-IgG Card for 15 minutes at 37 2C.
7. After incubation, centrifuge the gel card(s) in the MTS Centrifuge at the preset conditions.
8. For manual readings, observe the front and the back of each microtube macroscopically and record
reactions as described in the interpretation section of the corresponding MTS Gel Card package insert.

1
AHG Crossmatch Procedure:
Donor Unit 0.8% Cell Preparation, using packed red blood cells from donor unit segments or pilot tubes
1. Label a test tube for each donor to be tested.
2. Dispense 1.0 mL of MTS Diluent 2into the labeled tube(s). Add 10 L of the donor packed red blood
cells.
3. Mix gently to resuspend. The final red blood cell suspensions should be approximately 0.8%.

Antiglobulin Crossmatch Test Procedure

1. Visually inspect each gel card before use. Each microtube should have a clear liquid layer on top of
opaque gel.
2. Label the MTS Anti-IgG Card with the appropriate identification.
3. Remove the foil seal from the gel card or from the individual microtubes used for testing
4. Add 50 L of the 0.8% donor red blood cell suspension to the appropriate microtube.
5. Add 25L of recipient serum or plasma to the microtubes.
6. Incubate the MTS Anti-IgG Card for 15 minutes at 37 2C.
7. After incubation, centrifuge the gel card(s) in the MTS Centrifuge at the preset conditions.
8. For manual readings, observe the front and the back of each microtube macroscopically and record
reactions as described in the interpretation section of the corresponding MTS Gel Card package insert.

The CHEO courses are evaluated using internal Hybrid or Online Course Review Tools based on
criteria from project colleges' Quality Assurance Standards developed by faculty and instructional
designers. Periodic course review is ongoing.

Consortium for Healthcare Education Online project material by CHEO Project TAACCCT Round 2 is licensed under a
Creative Commons Attribution 4.0 International LicenseThis product was funded by a grant awarded by the U.S. Department of Labors
Employment and Training Administration. The product was created by the grantee and does not necessarily reflect the official position of the U.S.
Department of Labor. The Department of Labor makes no guarantees, warranties, or assurances of any kind, express or implied, with respect to
such information, including any information on linked sites and including, but not limited to, accuracy of the information or its completeness,
timeliness, usefulness, adequacy, continued availability, or ownership.